Thyroid Gland Disorder Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Indication (Hypothyroidism, Hyperthyroidism), By Route of Administration (Oral, Intravenous, Others), By Distribution Channel (Wholesaler/Distributors, Retail Chain, Online Distribution, Others), By Region & Competition, 2021-2031F

January 2026 | 180 pages | ID: TCF29B1F7F9EEN
TechSci Research

Abstracts

The Global Thyroid Gland Disorder Treatment Market is projected to expand from USD 2.93 Billion in 2025 to USD 3.77 Billion by 2031, registering a CAGR of 4.29%. This market includes various pharmaceutical interventions and therapies, including levothyroxine and radioactive iodine, designed to restore hormonal equilibrium in individuals suffering from hypothyroidism, hyperthyroidism, or thyroid cancer. Growth is largely propelled by the rising global incidence of thyroid dysfunction and an aging demographic requiring long-term disease management. For instance, the American Cancer Society estimates that roughly 44,020 new thyroid cancer cases will arise in the United States in 2025. This significant patient load highlights the urgent necessity for a reliable supply of therapeutics and stimulates demand for effective treatment solutions within international healthcare systems.

However, the sector encounters substantial hurdles due to the strict regulatory frameworks governing the approval of new treatments. Rigorous compliance requirements and comprehensive safety validations for new drug formulations frequently prolong development schedules and escalate operational expenses. These regulatory obstacles effectively retard the pace at which innovative therapies reach the commercial market, potentially hindering expansion in emerging economies that are still developing their healthcare infrastructure.

Market Driver

The rising global prevalence of thyroid disorders serves as a major driver for market growth, creating a critical need for a reliable supply of hormone replacement therapies. With hypothyroidism rates increasing due to aging demographics and enhanced diagnostic capabilities, reliance on standard treatments such as levothyroxine is intensifying. This consistent patient demand generates substantial commercial volume for established pharmaceutical companies, securing steady revenue within the chronic care sector. For example, Merck Group?s November 2025 report indicated that its primary thyroid medication, Euthyrox, achieved 9.6% organic net sales growth driven by robust global demand. Furthermore, an August 2025 press release from the U.S. Food and Drug Administration noted that approximately 22 million patients in the United States were prescribed levothyroxine in 2024, evidencing the heavy disease burden.

Concurrently, the uptake of novel drug formulations is broadening revenue sources beyond traditional generic hormone replacements. Pharmaceutical companies are actively investing in biologics and targeted therapies to manage complex conditions like Thyroid Eye Disease (TED) and refractory thyroid cancers. These innovations provide high-value alternatives to conventional therapies, gaining market share through better clinical results and premium pricing. Amgen Inc., in its third-quarter 2025 financial results, reported that global sales of Tepezza, a targeted treatment for thyroid eye disease, rose by 15% year-over-year to $560 million. This increase in adoption highlights a significant industry shift toward specialized treatments designed to meet specific, unaddressed needs across the thyroid disorder landscape.

Market Challenge

Stringent regulatory frameworks represent a major obstacle to the growth of the Global Thyroid Gland Disorder Treatment Market. Developers are required to navigate intricate compliance protocols and execute comprehensive clinical trials to confirm the safety and efficacy of new treatments. These rigorous demands substantially increase operational expenses and prolong development cycles, resulting in bottlenecks that delay the commercial introduction of innovative drug formulations. As a result, the market struggles to adapt quickly to the changing requirements of healthcare providers and patients, which leads to lost revenue potential and decelerated industry advancement.

The consequences of these regulatory delays are exacerbated by the significant disease burden necessitating prompt and effective care. The American Thyroid Association estimates that in 2025, around 20 million Americans suffer from some type of thyroid condition. This immense patient volume underscores the disparity between the urgent need for advanced therapies and the sluggish pace of product approvals. By hindering the rapid market entry of new treatments, regulatory barriers restrict the industry's capacity to address the needs of this extensive patient population, thereby impeding overall market expansion.

Market Trends

The integration of AI-driven diagnostic and monitoring solutions is revolutionizing the clinical management of thyroid nodules by improving imaging precision and workflow efficiency. Manufacturers are actively incorporating deep learning algorithms into ultrasound systems to aid radiologists in the consistent detection, segmentation, and classification of thyroid lesions. This technological evolution mitigates the subjectivity common in manual examinations, standardizing risk assessment protocols and potentially lowering the rate of unnecessary biopsies for benign nodules. For instance, Samsung Medison?s November 2025 press release regarding its new R20 ultrasound system highlights the inclusion of over a dozen AI tools designed to automate measurements and offer real-time diagnostic guidance for complex cases.

Simultaneously, the proliferation of targeted tyrosine kinase inhibitors for thyroid cancer is redefining treatment options for patients with radioactive iodine-refractory disease. As knowledge regarding the molecular causes of thyroid malignancy expands, there is a marked increase in the adoption of precision oncology therapies that block specific pathways like VEGFR and RET. This transition towards molecularly targeted treatments is fueling significant revenue growth for pharmaceutical companies, as these oral medications emerge as standard alternatives to traditional chemotherapy. Exelixis Inc. reported in May 2025 that its flagship tyrosine kinase inhibitor, Cabometyx, achieved net product revenues of $513.3 million for the first quarter, driven by rising demand across oncology indications, including differentiated thyroid cancer.

Key Market Players

• Abbvie Inc.
• Amgen Inc.
• GSK Plc
• Merck KGaA
• Viatris Inc.
• Novartis AG
• Pfizer Inc.
• Takeda Pharmaceutical Company Limited
• Elexis Inc.
• IBSA Group

Report Scope

In this report, the Global Thyroid Gland Disorder Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Thyroid Gland Disorder Treatment Market, By Indication
• Hypothyroidism
• Hyperthyroidism
• Thyroid Gland Disorder Treatment Market, By Route of Administration
• Oral
• Intravenous
• Others
• Thyroid Gland Disorder Treatment Market, By Distribution Channel
• Wholesaler/Distributors
• Retail Chain
• Online Distribution
• Others
• Thyroid Gland Disorder Treatment Market, By Region
• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Thyroid Gland Disorder Treatment Market.

Available Customizations:

Global Thyroid Gland Disorder Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Contents

1. PRODUCT OVERVIEW

1.1. Market Definition
1.2. Scope of the Market
  1.2.1. Markets Covered
  1.2.2. Years Considered for Study
  1.2.3. Key Market Segmentations

2. RESEARCH METHODOLOGY

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations

3. EXECUTIVE SUMMARY

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends

4. VOICE OF CUSTOMER

5. GLOBAL THYROID GLAND DISORDER TREATMENT MARKET OUTLOOK

5.1. Market Size & Forecast
  5.1.1. By Value
5.2. Market Share & Forecast
  5.2.1. By Indication (Hypothyroidism, Hyperthyroidism)
  5.2.2. By Route of Administration (Oral, Intravenous, Others)
  5.2.3. By Distribution Channel (Wholesaler/Distributors, Retail Chain, Online Distribution, Others)
  5.2.4. By Region
  5.2.5. By Company (2025)
5.3. Market Map

6. NORTH AMERICA THYROID GLAND DISORDER TREATMENT MARKET OUTLOOK

6.1. Market Size & Forecast
  6.1.1. By Value
6.2. Market Share & Forecast
  6.2.1. By Indication
  6.2.2. By Route of Administration
  6.2.3. By Distribution Channel
  6.2.4. By Country
6.3. North America: Country Analysis
  6.3.1. United States Thyroid Gland Disorder Treatment Market Outlook
    6.3.1.1. Market Size & Forecast
      6.3.1.1.1. By Value
    6.3.1.2. Market Share & Forecast
      6.3.1.2.1. By Indication
      6.3.1.2.2. By Route of Administration
      6.3.1.2.3. By Distribution Channel
  6.3.2. Canada Thyroid Gland Disorder Treatment Market Outlook
    6.3.2.1. Market Size & Forecast
      6.3.2.1.1. By Value
    6.3.2.2. Market Share & Forecast
      6.3.2.2.1. By Indication
      6.3.2.2.2. By Route of Administration
      6.3.2.2.3. By Distribution Channel
  6.3.3. Mexico Thyroid Gland Disorder Treatment Market Outlook
    6.3.3.1. Market Size & Forecast
      6.3.3.1.1. By Value
    6.3.3.2. Market Share & Forecast
      6.3.3.2.1. By Indication
      6.3.3.2.2. By Route of Administration
      6.3.3.2.3. By Distribution Channel

7. EUROPE THYROID GLAND DISORDER TREATMENT MARKET OUTLOOK

7.1. Market Size & Forecast
  7.1.1. By Value
7.2. Market Share & Forecast
  7.2.1. By Indication
  7.2.2. By Route of Administration
  7.2.3. By Distribution Channel
  7.2.4. By Country
7.3. Europe: Country Analysis
  7.3.1. Germany Thyroid Gland Disorder Treatment Market Outlook
    7.3.1.1. Market Size & Forecast
      7.3.1.1.1. By Value
    7.3.1.2. Market Share & Forecast
      7.3.1.2.1. By Indication
      7.3.1.2.2. By Route of Administration
      7.3.1.2.3. By Distribution Channel
  7.3.2. France Thyroid Gland Disorder Treatment Market Outlook
    7.3.2.1. Market Size & Forecast
      7.3.2.1.1. By Value
    7.3.2.2. Market Share & Forecast
      7.3.2.2.1. By Indication
      7.3.2.2.2. By Route of Administration
      7.3.2.2.3. By Distribution Channel
  7.3.3. United Kingdom Thyroid Gland Disorder Treatment Market Outlook
    7.3.3.1. Market Size & Forecast
      7.3.3.1.1. By Value
    7.3.3.2. Market Share & Forecast
      7.3.3.2.1. By Indication
      7.3.3.2.2. By Route of Administration
      7.3.3.2.3. By Distribution Channel
  7.3.4. Italy Thyroid Gland Disorder Treatment Market Outlook
    7.3.4.1. Market Size & Forecast
      7.3.4.1.1. By Value
    7.3.4.2. Market Share & Forecast
      7.3.4.2.1. By Indication
      7.3.4.2.2. By Route of Administration
      7.3.4.2.3. By Distribution Channel
  7.3.5. Spain Thyroid Gland Disorder Treatment Market Outlook
    7.3.5.1. Market Size & Forecast
      7.3.5.1.1. By Value
    7.3.5.2. Market Share & Forecast
      7.3.5.2.1. By Indication
      7.3.5.2.2. By Route of Administration
      7.3.5.2.3. By Distribution Channel

8. ASIA PACIFIC THYROID GLAND DISORDER TREATMENT MARKET OUTLOOK

8.1. Market Size & Forecast
  8.1.1. By Value
8.2. Market Share & Forecast
  8.2.1. By Indication
  8.2.2. By Route of Administration
  8.2.3. By Distribution Channel
  8.2.4. By Country
8.3. Asia Pacific: Country Analysis
  8.3.1. China Thyroid Gland Disorder Treatment Market Outlook
    8.3.1.1. Market Size & Forecast
      8.3.1.1.1. By Value
    8.3.1.2. Market Share & Forecast
      8.3.1.2.1. By Indication
      8.3.1.2.2. By Route of Administration
      8.3.1.2.3. By Distribution Channel
  8.3.2. India Thyroid Gland Disorder Treatment Market Outlook
    8.3.2.1. Market Size & Forecast
      8.3.2.1.1. By Value
    8.3.2.2. Market Share & Forecast
      8.3.2.2.1. By Indication
      8.3.2.2.2. By Route of Administration
      8.3.2.2.3. By Distribution Channel
  8.3.3. Japan Thyroid Gland Disorder Treatment Market Outlook
    8.3.3.1. Market Size & Forecast
      8.3.3.1.1. By Value
    8.3.3.2. Market Share & Forecast
      8.3.3.2.1. By Indication
      8.3.3.2.2. By Route of Administration
      8.3.3.2.3. By Distribution Channel
  8.3.4. South Korea Thyroid Gland Disorder Treatment Market Outlook
    8.3.4.1. Market Size & Forecast
      8.3.4.1.1. By Value
    8.3.4.2. Market Share & Forecast
      8.3.4.2.1. By Indication
      8.3.4.2.2. By Route of Administration
      8.3.4.2.3. By Distribution Channel
  8.3.5. Australia Thyroid Gland Disorder Treatment Market Outlook
    8.3.5.1. Market Size & Forecast
      8.3.5.1.1. By Value
    8.3.5.2. Market Share & Forecast
      8.3.5.2.1. By Indication
      8.3.5.2.2. By Route of Administration
      8.3.5.2.3. By Distribution Channel

9. MIDDLE EAST & AFRICA THYROID GLAND DISORDER TREATMENT MARKET OUTLOOK

9.1. Market Size & Forecast
  9.1.1. By Value
9.2. Market Share & Forecast
  9.2.1. By Indication
  9.2.2. By Route of Administration
  9.2.3. By Distribution Channel
  9.2.4. By Country
9.3. Middle East & Africa: Country Analysis
  9.3.1. Saudi Arabia Thyroid Gland Disorder Treatment Market Outlook
    9.3.1.1. Market Size & Forecast
      9.3.1.1.1. By Value
    9.3.1.2. Market Share & Forecast
      9.3.1.2.1. By Indication
      9.3.1.2.2. By Route of Administration
      9.3.1.2.3. By Distribution Channel
  9.3.2. UAE Thyroid Gland Disorder Treatment Market Outlook
    9.3.2.1. Market Size & Forecast
      9.3.2.1.1. By Value
    9.3.2.2. Market Share & Forecast
      9.3.2.2.1. By Indication
      9.3.2.2.2. By Route of Administration
      9.3.2.2.3. By Distribution Channel
  9.3.3. South Africa Thyroid Gland Disorder Treatment Market Outlook
    9.3.3.1. Market Size & Forecast
      9.3.3.1.1. By Value
    9.3.3.2. Market Share & Forecast
      9.3.3.2.1. By Indication
      9.3.3.2.2. By Route of Administration
      9.3.3.2.3. By Distribution Channel

10. SOUTH AMERICA THYROID GLAND DISORDER TREATMENT MARKET OUTLOOK

10.1. Market Size & Forecast
  10.1.1. By Value
10.2. Market Share & Forecast
  10.2.1. By Indication
  10.2.2. By Route of Administration
  10.2.3. By Distribution Channel
  10.2.4. By Country
10.3. South America: Country Analysis
  10.3.1. Brazil Thyroid Gland Disorder Treatment Market Outlook
    10.3.1.1. Market Size & Forecast
      10.3.1.1.1. By Value
    10.3.1.2. Market Share & Forecast
      10.3.1.2.1. By Indication
      10.3.1.2.2. By Route of Administration
      10.3.1.2.3. By Distribution Channel
  10.3.2. Colombia Thyroid Gland Disorder Treatment Market Outlook
    10.3.2.1. Market Size & Forecast
      10.3.2.1.1. By Value
    10.3.2.2. Market Share & Forecast
      10.3.2.2.1. By Indication
      10.3.2.2.2. By Route of Administration
      10.3.2.2.3. By Distribution Channel
  10.3.3. Argentina Thyroid Gland Disorder Treatment Market Outlook
    10.3.3.1. Market Size & Forecast
      10.3.3.1.1. By Value
    10.3.3.2. Market Share & Forecast
      10.3.3.2.1. By Indication
      10.3.3.2.2. By Route of Administration
      10.3.3.2.3. By Distribution Channel

11. MARKET DYNAMICS

11.1. Drivers
11.2. Challenges

12. MARKET TRENDS & DEVELOPMENTS

12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments

13. GLOBAL THYROID GLAND DISORDER TREATMENT MARKET: SWOT ANALYSIS

14. PORTER'S FIVE FORCES ANALYSIS

14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products

15. COMPETITIVE LANDSCAPE

15.1. Abbvie Inc.
  15.1.1. Business Overview
  15.1.2. Products & Services
  15.1.3. Recent Developments
  15.1.4. Key Personnel
  15.1.5. SWOT Analysis
15.2. Amgen Inc.
15.3. GSK Plc
15.4. Merck KGaA
15.5. Viatris Inc.
15.6. Novartis AG
15.7. Pfizer Inc.
15.8. Takeda Pharmaceutical Company Limited
15.9. Elexis Inc.
15.10. IBSA Group

16. STRATEGIC RECOMMENDATIONS

17. ABOUT US & DISCLAIMER